CyTOF technology in the fight against infectious disease
From SARS-CoV-2 to HIV, malaria, S. Typhi, Ebola and smallpox, mass cytometry is driving understanding of infectious disease and innovation in vaccine development.
Uncovering the immunological mechanisms of infection and vaccination
Investigators working on infectious disease adopted mass cytometry early on because of its ability to identify immune cell populations with breadth and depth simultaneously. The often-limited sample volumes available for clinical research studies mean researchers need to maximize the information gathered from every single cell.
By quickly and reproducibly profiling 50 or more phenotypic and functional markers in a single tube of sample without requiring extra tubes to account for fluorescence spillover or time-consuming genomic analysis, mass cytometry offers a clear advantage over other single-cell technologies.
Hundreds of publications attest to the positive impact of CyTOF® on infectious disease research.
When the SARS-CoV-2 pandemic arrived, the high-dimensional power and data quality of mass cytometry was quickly leveraged by immunologists and consortia around the world to sort out the puzzle of COVID-19 disease and the efficacy of vaccines against the virus and its variants.
The Maxpar® Direct™ Immune Profiling Assay™: Adoption for use in COVID-19 clinical research
This dry-format high-parameter mass cytometry panel kit has proven run-to-run and site-to-site reproducibility, is easy to use and can be run with small amounts of either human PBMC or whole blood. The 30-marker backbone panel is expandable, with room to add 14 or more markers. When paired with Maxpar Pathsetter™ software, a detailed analytic report on 37 immune cell populations is ready in 5 minutes or less.
Find out more about this assay kit and automated data analysis solution.
As of August 2021, over 60 peer-reviewed publications and preprints have been published related to COVID-19 research, and at least 12 National Clinical Trials related to the disease or vaccination trials are employing mass cytometry.
Mass Cytometry in Vaccine Development
Patrick Reeves, PhD
Instructor in Medicine, Harvard Medical School Team Leader, Vaccine and Immunotherapy Center Massachusetts General Hospital
Revealing the Peculiarities of Immune Cells during COVID-19
Andrea Cossarizza, MD, PhD
Professor of Immunology and Pathology
University of Modena and Reggio Emilia School of Medicine and Surgery
Systems-Level Immune Dynamics from Acute to Recovery Phase of Severe COVID-19
Petter Brodin, MD, PhD
Associate Professor and Consultant Physician
Science for Life Laboratory, Karolinska Institutet, and Department of Pediatric Rheumatology
Karolinska University Hospital, Stockholm
A Complete Immune Monitoring Solution with CyTOF: Ideal for Pandemics and Beyond
Frederik De Smet, MSc, PhD
University of Leuven, Belgium
Unless explicitly and expressly stated otherwise, all Fluidigm products are provided for Research Use Only and Not For Use in Diagnostic Procedures. For more information see www.fluidigm.com/legal/notices.